14 Results for "

NSD2 degrader

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "NSD2 degrader" in MCE Product Catalog:

Cat. No.: HY-161574
CAS No.: 3061315-33-8
Research Areas:  

Cancer

LLC0424 is a potent and selective cereblon-based PROTAC nuclear receptor-binding SET domain-containing 2 (NSD2) degrader. LLC0424 effectively degraded NSD2 with a DC50 of 20 nM in RPMI-8402 cells. LLC0424 selectively induces NSD2 degradation in a cereblon- and proteasome-dependent fashion. (Blue: CRBN ligand (HY-14658), Black: linker (HY-40002); Pink: NSD2 inhibitor (HY-161575)) .
loading...
    loading...
Cat. No.: HY-157251
CAS No.: 2929304-61-8
Purity:  99.92%
Research Areas:  

Cancer

UNC8153 TFA is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 TFA reduces the cellular levels of both NSD2 protein (DC50 in cell U2OS is 0.35 μM) and the H3K36me2 chromatin mark. UNC8153 TFA contains a simple warhead that confers proteasome-dependent degradation of NSD2 .
loading...
    loading...
Cat. No.: HY-157251A
CAS No.: 2929304-60-7
Purity:  99.13%
Research Areas:  

Cancer

UNC8153 is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 reduces the cellular levels of both NSD2 protein (DC50 in cell U2OS is 0.35 μM) and the H3K36me2 chromatin mark. UNC8153 contains a simple warhead that confers proteasome-dependent degradation of NSD2 .
loading...
    loading...
Cat. No.: HY-161575
NSD2 ligand 1 is a NSD2 ligand. NSD2 ligand 1 can be used for synthesis of LLC0424 (HY-161574) (a PROTAC NSD2 degrader) .
loading...
    loading...
Cat. No.: HY-161796A
CAS No.: 2929304-06-1
Research Areas:  

Cancer

UNC8732 (TFA) is a NSD2 inhibitor and degrader .
loading...
    loading...
Cat. No.: HY-184968
CAS No.: 3108071-48-0
Research Areas:  

Cancer

PROTAC NSD2 degrader-1 is a PROTAC degrader that selectively targets NSD2, with a DC50 of 0.37 μM. PROTAC NSD2 degrader-1 induces selective degradation of long and short isoforms of NSD2 containing the PWWP1 domain by forming a ternary complex with FBXO22. NSD2 degradation mediated by PROTAC NSD2 degrader-1 depends on the ubiquitin-proteasome system and the neddylation pathway. PROTAC NSD2 degrader-1 can be used in cancer-related research such as non-small cell lung cancer, multiple myeloma and prostate cancer .
loading...
    loading...
Cat. No.: HY-161796
CAS No.: 2929304-05-0
Research Areas:  

Cancer

UNC8732 is an NSD2 degrader with a Kd value of 76 nM for NSD2, and achieves highly selective degradation of NSD2 across the detectable proteome. UNC8732 acts as a prodrug; its primary amine is metabolized to an aldehyde, which forms a reversible covalent interaction with Cys326 in the FIST_C domain of FBXO22, recruiting the SCFFBXO22 ubiquitin ligase complex to mediate polyubiquitination and proteasomal degradation of NSD2. UNC8732 serves as a chemical probe to investigate NSD2-associated disease phenotypes and study the functions of NSD2 in nuclear signaling and epigenetics. UNC8732 can be used in studies of acute lymphoblastic leukemia .
loading...
    loading...
Cat. No.: HY-178322
Research Areas:  

Cancer

UNC10415667 is a non-competitive, non-prodrug NSD2 degrader with a DC50 of 460 nM in U2OS NSD2 HiBiT cells. UNC10415667 forms a reversible covalent hemithioacetal bond with Cys326 of FBXO22, promoting the formation of a ternary complex with FBXO22 and NSD2, which in turn triggers the polyubiquitination and degradation of NSD2 via the ubiquitin-proteasome system. UNC10415667 can form complexes with FBXO22, NSD2 and BACH1 simultaneously, driving the synchronized degradation of NSD2 and BACH1 without competition. UNC10415667 can be used in research related to multiple myeloma, acute lymphoblastic leukemia, and prostate cancer .
loading...
    loading...
Cat. No.: HY-170674
Research Areas:  

Cancer

ND-L11B is a potent degrader of nuclear receptor binding SET domain protein 2 (NSD2) and RE-IIBP, with the DC50 of 1.48 and 0.8 μM, the Dmax is closed to 80 % .
loading...
    loading...
Cat. No.: HY-170674A
Research Areas:  

Cancer

ND-L11B TFA is a potent degrader of nuclear receptor binding SET domain protein 2 (NSD2) and RE-IIBP, with the DC50 of 1.48 and 0.8 μM, the Dmax is closed to 80 % .
loading...
    loading...
Cat. No.: HY-178321
Research Areas:  

Cancer

UNC10088 is a molecular glue targeting NSD2. UNC10088 mediates the formation of a stable ternary complex between SCFFBXO22 and the NSD2 PWWP1 domain. UNC10088 promotes ubiquitination of the SCFFBXO22-dependent NSD2 PWWP1 domain through reversible covalent bonding with the C326 region of FBXO22. UNC10088 could be used in cancer research .
loading...
    loading...
Cat. No.: HY-W1005059
CAS No.: 42472-93-5
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

N-Methylthalidomide is a cereblon ligand derivative that acts as an E3 ubiquitin ligase ligand for the synthesis of PROTAC LLC0424N (HY-185557). LLC0424N serves as a negative control for NSD2 PROTAC degrader LLC0424 (HY-161574), with weak ability to induce NSD2 degradation and low growth inhibitory effect on cancer cells carrying NSD2 mutations .
loading...
    loading...
Cat. No.: HY-185557
CAS No.: 3063448-59-6
Research Areas:  

Cancer

LLC0424N is a negative control compound designed by methylating the thalidomide moiety of LLC0424 (HY-161574). LLC0424N shows does not induce NSD2 degradation and inhibit growth of acute lymphoblastic leukemia cells with NSD2 mutation. LLC0424N can be used for the research of acute lymphoblastic leukemia .
loading...
    loading...
Cat. No.: HY-161576
CAS No.: 2636798-54-2
Research Areas:  

Cancer

Thalidomide-Pip-N-boc is a conjugate of E3 ligase ligand and linker. Thalidomide-Pip-N-boc is utilized for synthesis of PROTAC Degrader LLC0424 (HY-161574) .
loading...
    loading...
  • 1